12 July 2019 - New treatment can help Canadians living with haemophilia A better manage their bleeding episodes ...
8 July 2019 - All aspects of the Biotest Therapy Business Unit acquisition are successfully completed. ...
4 July 2019 - Xembify is Grifols’ first 20% subcutaneous immunoglobulin for the treatment of primary immunodeficiencies. ...
20 June 2019 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Esperoct for the treatment ...
10 May 2019 - ADMA Biologics announces that the U.S. FDA has approved the Company’s prior approval supplement for Bivigam (immune ...
1 April 2019 - Approved for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents (12 to ...
19 February 2019 - Novo Nordisk today announced that the US FDA has approved the biologics license application for Esperoct ...
7 January 2019 - ADMA Biologics announces that the Company has submitted responses to the U.S. FDA complete response letter received ...
19 December 2018 - FDA issues complete response letter for drug substance, approves supplement for drug product. ...
4 December 2018 - Today the U.S. FDA updated a draft guidance entitled, “Bacterial Risk Control Strategies for Blood Collection Establishments ...
30 November 2018 - EMA has published revised guidelines on the tests and studies needed to support marketing authorisation applications ...
27 November 2018 - The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical ...
26 November 2018 - Octapharma today announced that the Swiss Agency for Therapeutic Products, Swissmedic, granted marketing authorisation to its new ...
26 November 2018 - Canadian children now have access to Adynovate, which offers a twice-weekly prophylaxis dosing schedule and on-demand control ...
24 October 2018 - Extended half-life product that offers a reduction in dosing frequency and improved bleeding protection. ...